|
||||||||||||||||
| HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
| Cambridge Healthtech Institute's BIOTECH EXECUTIVE FORUM:Shifting from Platform to Drug Development | ||||||||||||||||
| January 28, 2003 | ||||||||||||||||
|
Cambridge Healthtech Institute, San Diego Concourse, San Diego, CA June 16-17, 2003 The pharmaceutical industry faces a crisis of productivity in R&D, and hundreds of new companies have been founded based on tools that can aid in improving drug development. There is a growing consensus, however, that the business model of a tool provider faces enormous challenges, compounded by being out of favor by the investment community. In order to obtain new, or additional funding, many technology companies are remaking themselves into drug discovery companies, employing their proprietary technology not as a service for others, but for the in-house discovery of therapeutics. Such a shift is business strategy may be consistent with conventional wisdom, but it hardly represents a shift toward a low-risk approach. The same reason that undercuts the viability of the tool business strategy, the need to customize and integrate different tools as needed for different development projects, represents a challenge that must be overcome to be a successful discovery company. Additional tools will need to be acquired, existing personnel will often be poorly suited for the changing need of the business, and discovery is an expensive, high risk business that requires plenty of funding and plenty of time. Some companies recognized the potential value of this shift in business strategy and began morphing their company several years ago. For more companies, this recognition and response is more recent. The Biotech Executive Forum will feature sage advice and valuable experience from CEOs and VPs at leading companies who have made this transition, or are presently in the process. Heavy in case studies, this timely conference can provide you with guidance and advice that can help you chart a successful path through the treacherous waters of such a strategy.
|
||||||||||||||||
| Organized by: | Cambridge Healthtech Institute | |||||||||||||||
| Invited Speakers: | Gunnar Weikert, CEO and Chairman, Inventages John D. Mendlein, Chairman and CEO, Affinium Pharmaceuticals David Brown, Ph.D., Chief Executive Officer & President, Cellzome Ted W. Love, President and CEO, Hyseq |
|||||||||||||||
| Deadline for Abstracts: | May 9, 2003 | |||||||||||||||
| Registration: | Available Online call:617-630-1300/fax:617-630-1325 e-mail: chi@healthtech.com | |||||||||||||||
| E-mail: | eeskedal@healthtech.com | |||||||||||||||
| Posted by: | elaine eskedal | |||||||||||||||
| Host: | wks152.healthtech.com | |||||||||||||||
|
||||||||||||||||
|
Generated by meetings and positions 5.0 by Kai Garlipp |
||||||||||||||||